<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000402</url>
  </required_header>
  <id_info>
    <org_study_id>07-641</org_study_id>
    <nct_id>NCT01000402</nct_id>
  </id_info>
  <brief_title>Juvenile Bipolar Disorder Outpatient Program</brief_title>
  <acronym>ProCAB</acronym>
  <official_title>Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an outpatient program for children and adolescents with bipolar disorders. The
      naturalistic approach of the program will allow a proper investigation of the disorder,
      assessment of environmental and biological factors, the conduction of treatment studies, and
      follow-up of the subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

      Age 6-17 years old, male and female. Bipolar Disorder I, II, and NOS (subjects presenting
      episodes of distinct abnormally and persistently elevated, expansive, or irritable mood,
      accompanied by at least three -or four if the mood is only irritable - Criteria B symptoms
      and present to a significant degree for at least 24 hours.

      Severe Mood Dysregulation (SMD), as defined by Brotman et al. (American Journal of
      Psychiatry, 2007)

      Exclusion criteria:

      Presence of a diagnosis of Pervasive Developmental Disorder, Schizophrenia, Drug Use
      Disorder, and any other counter indications to outpatient treatment (significant suicide or
      homicide risk)

      Diagnosis:

      K-SADS-PL-W WASI Clinical Interview

      Outcome Measures:

      CBCL for general psychopathology YMRS, CMRS-P, CMRS-T for manic symptoms CDRS and CDI for
      depressive symptoms SNAP-IV for ADHD symptoms Scared-C and Scared-P for anxiety symptoms CGI
      for clinical impression, CGAS for global functioning Petersen Pubertal Scale Mood Symptom
      Questionnaire for SMD Screening tests for leaning disorders Family Environmental Scale, Life
      Events Scale, Expressed Emotion Adjective Checklist, Resilience Scale, Quality of Life for
      environmental and psychological factors Medication Adverse Events Checklist
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in manic and depressive symptoms over time using YMRS, CMRS-P, CDRS, and CDI</measure>
    <time_frame>Naturalistic Study - 2-year follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Polymorphisms at candidate genes for Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder</measure>
    <time_frame>Naturalistic 2-year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in ADHD symptoms according to SNAP-IV</measure>
    <time_frame>Naturalistic 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Anxiety symptoms according to the SCARED-C and SCARED-P</measure>
    <time_frame>Naturalistic 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in family functioning according to the FES-R, individual functioning according to the EEAC and Resilience Scale, environmental factors according to the Stressful Life Events Scale</measure>
    <time_frame>Naturalistic 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and onset of adverse events secondary to treatment</measure>
    <time_frame>Naturalistic 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SMD symptoms according to the Mood Symptom Questionnaire</measure>
    <time_frame>Naturalistic 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in general functioning according to the CGI and the CGAS</measure>
    <time_frame>Naturalistic 2-year follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Psychopharmacotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No specific arms; Treatment decision based on available guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psychopharmacotherapy</intervention_name>
    <description>Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day</description>
    <arm_group_label>Psychopharmacotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6-18 years-old;

          -  Bipolar Disorder I, II or NOS

          -  Severe Mood Dysregulation

        Exclusion Criteria:

          -  Schizophrenia

          -  Pervasive Developmental Disorder

          -  Drug use disorder

          -  Severe suicidal or homicidal risk, counterindicating outpatient treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis A Rohde, D.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silza Tramontina, D.Sc.</last_name>
    <phone>+55 51 21018094</phone>
    <email>silza.tramontina@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clarissa F Paim</last_name>
    <phone>+55 51 21018094</phone>
    <email>cfpaim@hcpa.ufrgs.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90350-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarissa F Paim</last_name>
      <phone>+55 51 21018094</phone>
      <email>cfpaim@hcpa.ufrgs.br</email>
    </contact>
    <contact_backup>
      <last_name>Silza Tramontina, D.Sc.</last_name>
      <phone>+55 51 21018094</phone>
      <email>silza.tramontina@terra.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Luis A Rohde, D.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silza Tramontina, D.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristian P Zeni, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carla R Ketzer, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel F Pheula, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernanda V Krieger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Petresco, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta S Coelho, B.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriana F Perez, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lanuzia Brum, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana P Guimaraes, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrique T Ludwig</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.ufrgs.br/procab</url>
    <description>Official Website of the ProCAB Outpatient Program</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>October 22, 2009</last_update_submitted>
  <last_update_submitted_qc>October 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Luis Augusto Paim Rohde</name_title>
    <organization>Federal University of Rio Grande do Sul</organization>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Attention-Deficit/Hyperactivity Disorder</keyword>
  <keyword>Genetics</keyword>
  <keyword>Environmental Factors</keyword>
  <keyword>Family Factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

